Valeura Energy Inc. reported robust Q3 2026 results with oil production of 2.036 million barrels and average realized prices of $97.4 per barrel, boosting revenue to $196.1 million. The company made a significant oil discovery at the Suraphi field and approved development of the Bussabong gas field, diversifying its portfolio. Financially, Valeura ended the quarter with $385 million in cash and no debt, positioning it well for future growth and acquisitions in Southeast Asia. Production guidance for 2026 remains strong despite a planned shutdown at Wassana for upgrades.
Valeura Energy Inc. posted strong Q3 2026 results, including 2.036 million barrels oil production and $97.4 average price per barrel. For readers following the energy sector, here is Pluang's market snapshot as of Nov 11, 2026 13:01 WIB: 79 US energy stocks were priced, with 48 rising and 30 falling. Notable movers include EQT at USD 52.19 (+4.55%), NESR at USD 20.42 (+4.45%, 45% Sell / 55% Buy), and AR at USD 37.76 (+3.85%, 45% Sell / 55% Buy).
Rakuten Kobo's 2026 annual report highlights a shift in global reading habits towards niche communities and diverse genres like sports romances, dark romance, and cozy mysteries. The report notes the fragmentation of traditional bestseller lists as r...
Anthropic, an AI company, is reserving up to 20% of its initial public offering (IPO) shares specifically for retail investors. This allocation is significantly higher than the typical 5% to 10% usually offered to individual investors in IPOs. By doi...
DataParser by 17a-4 LLC now supports capturing Zoom AI meeting summaries along with transcripts and recordings for regulatory compliance. This solution helps firms retain, supervise, and search AI-generated content, closing gaps in archiving platform...
At the 9th China International Import Expo (CIIE), Shanghai Zhenhua Heavy Industries (ZPMC) signed import procurement contracts worth RMB 2.835 billion with 12 overseas suppliers including Siemens and ABB. This brings ZPMC's cumulative procurement co...
Devia, an AI platform spun out from Visium, has launched to help biopharma companies, CDMOs, and CROs manage GxP quality deviations more efficiently. It automates the entire deviation lifecycle from reporting to root cause analysis and CAPA, reducing...
